[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Colitis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 112 pages | ID: CF7F0E1C0018EN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Colitis PIPELINE HIGHLIGHTS
Colitis is one of the widely researched conditions during 2020 with 27 companies actively focusing on realizing pipeline’s potential. Development of Colitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Colitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Colitis.

Good progress is anticipated during 2020 and 2021 with Colitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Colitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Colitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Colitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Colitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Colitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Colitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Colitis DRUG PROFILES
Colitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Colitis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Colitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Colitis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 27 Colitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Colitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- AlfaSigma SpA, Apollo Endosurgery Inc , Citryll BV, Concenter BioPharma Silkim Ltd, enGene Inc , ExCellThera Inc, GeneFrontier Corp, Genfit SA , Immodulon Therapeutics Ltd, Immuron Ltd, Inflazome Ltd, Jubilant Biosys Ltd, MAKScientific LLC, Nippon Kayaku Co Ltd, Principia Biopharma Inc, Protagonist Therapeutics Inc, RDD Pharma Ltd , Riptide Bioscience Inc, Scholar Rock Inc, Serpinx BV, Soligenix Inc, Symbiotix Biotherapies Inc, Synthetic Biologics Inc, TaiRx Inc, TPCera Ltd , Vedanta Biosciences Inc, Vitality Biopharma Inc

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Colitis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO COLITIS

1.1 Colitis- Disease overview
1.2 Colitis- Market Size
1.3 Colitis- Companies Involved

2. COLITIS PIPELINE SNAPSHOT- 2020

2.1 Colitis Pipeline by Phase
2.2 Colitis Pipeline by Mechanism of Action
2.3 Colitis Pipeline by Route of Administration
2.4 Colitis Pipeline- New Molecular Entities
2.5 Colitis Pipeline- Orphan Drug Designation/ Special Designation

3. COLITIS DRUG PROFILES

3.1 Current Status
3.2 Colitis Drug Snapshot
3.3 Colitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 AlfaSigma SpA Colitis Pipeline Insights and Clinical Trials
4.2 Apollo Endosurgery Inc Colitis Pipeline Insights and Clinical Trials
4.3 Citryll BV Colitis Pipeline Insights and Clinical Trials
4.4 Concenter BioPharma Silkim Ltd Colitis Pipeline Insights and Clinical Trials
4.5 enGene Inc Colitis Pipeline Insights and Clinical Trials
4.6 ExCellThera Inc Colitis Pipeline Insights and Clinical Trials
4.7 GeneFrontier Corp Colitis Pipeline Insights and Clinical Trials
4.8 Genfit SA Colitis Pipeline Insights and Clinical Trials
4.9 Immodulon Therapeutics Ltd Colitis Pipeline Insights and Clinical Trials
4.10 Immuron Ltd Colitis Pipeline Insights and Clinical Trials
4.11 Inflazome Ltd Colitis Pipeline Insights and Clinical Trials
4.12 Jubilant Biosys Ltd Colitis Pipeline Insights and Clinical Trials
4.13 MAKScientific LLC Colitis Pipeline Insights and Clinical Trials
4.14 Nippon Kayaku Co Ltd Colitis Pipeline Insights and Clinical Trials
4.15 Principia Biopharma Inc Colitis Pipeline Insights and Clinical Trials
4.16 Protagonist Therapeutics Inc Colitis Pipeline Insights and Clinical Trials
4.17 RDD Pharma Ltd Colitis Pipeline Insights and Clinical Trials
4.18 Riptide Bioscience Inc Colitis Pipeline Insights and Clinical Trials
4.19 Scholar Rock Inc Colitis Pipeline Insights and Clinical Trials
4.20 Serpinx BV Colitis Pipeline Insights and Clinical Trials
4.21 Soligenix Inc Colitis Pipeline Insights and Clinical Trials
4.22 Symbiotix Biotherapies Inc Colitis Pipeline Insights and Clinical Trials
4.23 Synthetic Biologics Inc Colitis Pipeline Insights and Clinical Trials
4.24 TaiRx Inc Colitis Pipeline Insights and Clinical Trials
4.25 TPCera Ltd Colitis Pipeline Insights and Clinical Trials
4.26 Vedanta Biosciences Inc Colitis Pipeline Insights and Clinical Trials
4.27 Vitality Biopharma Inc Colitis Pipeline Insights and Clinical Trials

5. COLITIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications